The Growing Focus on Better Care for Cancer Cachexia

A Growing Need for Better Supportive Care

The global cancer cachexia sector was valued at around USD 2.71 billion in 2025 and is expected to reach approximately USD 4.37 billion by 2035, growing at a 4.9% CAGR between 2026 and 2035.

The rising global cancer burden is one of the main factors behind this growth. Lung, pancreatic, gastrointestinal, and other cancers can be associated with cachexia, creating a greater need for treatments that address appetite loss, muscle wasting, and metabolic changes.

What stands out to me is the growing shift toward treating cachexia as an important part of supportive oncology rather than looking at it only as a secondary symptom.

Treatment Approaches Are Expanding

Appetite stimulants currently account for the largest share of treatment use. These therapies can help patients improve appetite and calorie intake, which is particularly important when maintaining nutrition becomes difficult.

At the same time, cannabinoid receptor agonists are attracting more attention and are expected to grow quickly in the coming years. Researchers are also exploring anabolic agents, corticosteroids, metabolic therapies, and combination approaches.

The bigger opportunity is in developing treatments that go beyond appetite and directly address muscle loss and metabolic changes.

AI Is Bringing New Possibilities

AI is also starting to play a role in cancer cachexia research.

Researchers are exploring AI-based models that can identify patients at higher risk of developing cachexia, analyze biomarkers, and monitor changes in weight and muscle mass.

AI can also support drug discovery by helping researchers understand disease pathways and identify potential treatment candidates more efficiently.

Wearable devices and digital monitoring tools could become particularly useful in the future. Regular tracking of body weight, muscle condition, activity, and other indicators may help healthcare professionals identify changes earlier.

Personalized Treatment Is Becoming More Important

Not every patient experiences cancer cachexia in the same way. This is why personalized treatment is becoming an important area of research.

Researchers are increasingly looking at genetic, metabolic, nutritional, and clinical factors when developing treatment strategies. The goal is to understand which approach may work best for a particular patient instead of relying on a single treatment for everyone.

This could eventually lead to more targeted therapies and better supportive care plans.

Lung Cancer Currently Leads

Among different cancer types, lung cancer accounted for the largest share in 2025. The high incidence of lung cancer contributes to a significant number of patients experiencing cachexia-related complications.

Pancreatic cancer is expected to see faster growth in the coming years. Its aggressive progression and strong association with weight and muscle loss are increasing the need for more effective supportive treatments.

North America Remains Ahead

North America held the leading position in 2025, supported by advanced healthcare infrastructure, strong oncology research, clinical trials, and greater adoption of innovative therapies.

The U.S. continues to be a major contributor, with pharmaceutical companies and research organizations investing in new approaches for cancer cachexia.

Asia Pacific, however, is expected to experience faster growth through 2035. Expanding oncology infrastructure, rising cancer cases, increasing healthcare investments, and improving access to advanced treatments are creating new opportunities across countries such as India and China.